
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Division of Cancer Epidemiology and Genetics; 2 Institut Municipal d'Investigació Mèdica and 3 Universitat Pompeu Fabra, Barcelona, Spain; 4 Core Genotype Facility at the Advanced Technology Center of the National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland; 5 Universidad de Oviedo, Oviedo, Spain; 6 Consorci Hospitalari Parc Taulí, Sabadell, Spain; 7 Hospital Universitario de Elche, Elche, Spain; and 8 Unidad de Investigación, Hospital Unversitario de Canarias, La Laguna, Spain
Requests for reprints:. Montserrat García-Closas, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Room 7076, 6120 Executive Boulevard, MSC 7234, Rockville, MD 20852-7234. Phone: 301-435-3981; Fax: 301-402-0916; E-mail: montse{at}nih.gov
Nucleotide excision repair (NER) is critical for protecting against damage from carcinogens in tobacco smoke. We evaluated the influence of common genetic variation in the NER pathway on bladder cancer risk by analyzing 22 single nucleotide polymorphisms (SNP) in seven NER genes (XPC, RAD23B, ERCC1, ERCC2, ERCC4, ERCC5, and ERCC6). Our study population included 1,150 patients with transitional cell carcinoma of the urinary bladder and 1,149 control subjects from Spain. Odds ratios (OR) and 95% confidence intervals (95% CI) were adjusted for age, gender, region, and smoking status. Subjects with the variant genotypes for SNPs in four of the seven genes evaluated had small increases in bladder cancer risk compared to subjects with the homozygous wild-type genotypes: RAD23B IVS5-15A>G (OR, 1.3; 95% CI, 1.1-1.5; P = 0.01), ERCC2 R156R (OR, 1.3; 95% CI, 1.1-1.6; P = 0.006), ERCC1 IVS5+33A>C (OR, 1.2; 95% CI, 1.0-1.5; P = 0.06; Ptrend = 0.04), and ERCC5 M254V (OR, 1.4; 95% CI, 1.0-2.0; P = 0.04). A global test for pathway effects indicated that genetic variation in NER characterized by the 22 SNPs analyzed in this study significantly predicts bladder cancer risk (P = 0.04). Pairwise comparisons suggested that carrying variants in two genes could result in substantial increases in risk. Classification tree analyses suggested the presence of subgroups of individuals defined by smoking and NER genotypes that could have substantial increases in risk. In conclusion, these findings provide support for the influence of genetic variation in NER on bladder cancer risk. A detailed characterization of genetic variation in key NER genes is warranted and might ultimately help identify multiple susceptibility variants that could be responsible for substantial joint increases in risk. (Cancer Epidemiol Biomarkers Prev 2006;15(3):53642)
This article has been cited by other articles:
![]() |
E.L. Crawford, T. Blomquist, D.N. Mullins, Y. Yoon, D.R. Hernandez, M. Al-Bagdhadi, J. Ruiz, J. Hammersley, and J.C. Willey CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions Carcinogenesis, December 1, 2007; 28(12): 2552 - 2559. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chen, A. M. Kamat, M. Huang, H.B. Grossman, C. P. Dinney, S. P. Lerner, X. Wu, and J. Gu High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk Carcinogenesis, October 1, 2007; 28(10): 2160 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. An, Z. Liu, Z. Hu, G. Li, L.-E Wang, E. M. Sturgis, A. K. El-Naggar, M. R. Spitz, and Q. Wei Potentially Functional Single Nucleotide Polymorphisms in the Core Nucleotide Excision Repair Genes and Risk of Squamous Cell Carcinoma of the Head and Neck Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1633 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Figueroa, N. Malats, N. Rothman, F. X. Real, D. Silverman, M. Kogevinas, S. Chanock, M. Yeager, R. Welch, M. Dosemeci, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk Carcinogenesis, August 1, 2007; 28(8): 1788 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, M. Lai, H. Yang, J. Lin, M. Huang, H.B. Grossman, C. P. Dinney, and X. Wu Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer Carcinogenesis, March 1, 2007; 28(3): 698 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rothman, M. Garcia-Closas, and D. W Hein Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned Int. J. Epidemiol., February 1, 2007; 36(1): 23 - 28. [Full Text] [PDF] |
||||
![]() |
S. C. Sak, J. H. Barrett, A. B. Paul, D. T. Bishop, and A. E. Kiltie Comprehensive Analysis of 22 XPC Polymorphisms and Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2537 - 2541. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |